Guardant Health, Inc.

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-11 pm EST			5-day change	1st Jan Change
107.58 ^USD	+2.43%		+1.35%	+5.33%

Feb. 02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
Jan. 30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT

Guardant Health announces multi-year strategic collaboration agreement with Merck

Published on 01/19/2026 at 09:34 am EST

Reuters

Latest news about Guardant Health, Inc.

Feb. 02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
Jan. 30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
Jan. 22	Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	CI
Jan. 22	Guardant Health Receives FDA Approval for Colorectal Cancer Diagnostic	MT
Jan. 19	Guardant Health announces multi-year strategic collaboration agreement with Merck	RE
Jan. 19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI
Jan. 12	Guardant Health, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
Jan. 12	Guardant Health shares up 2.4% after preliminary Q4 revenue beats estimates	RE
Jan. 12	Independence, Under Review
Jan. 12	Guardant Health Sees 39% Rise in Q4 Preliminary Revenue	MT
Jan. 11	Guardant Health Q4 total revenue of approx $280 million	RE
Jan. 11	Guardant Health, Inc. Provides Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Jan. 08	Guardant Health, Inc.'S Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families	CI
Dec. 18	Guardant Health Insider Sold Shares Worth $9,402,220, According to a Recent SEC Filing	MT
Dec. 11	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S	CI
Dec. 11	Guardant Health Forms Collaboration With Trial Library to Increase US Access to Cancer Clinical Trials	MT
Dec. 11	Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing	MT
Dec. 11	Guardant Health Insider Sold Shares Worth $2,417,980, According to a Recent SEC Filing	MT
Dec. 09	Guardant Health, Inc. and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy	CI
Dec. 09	Guardant Health Insider Sold Shares Worth $3,241,621, According to a Recent SEC Filing	MT
Dec. 09	Guardant Health Insider Sold Shares Worth $8,288,742, According to a Recent SEC Filing	MT
Dec. 09	Guardant Health Insider Sold Shares Worth $3,066,817, According to a Recent SEC Filing	MT
Dec. 04	Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
Dec. 04	Certain Options of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
Dec. 04	Certain Restricted Stock Units of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,010

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 19 - Q4 2025 Earnings Release

More about the company